DCGI Approves Cipla’s Ciplostem Cell Therapy for Knee Osteoarthritis
Cipla has taken an amazing step into the world of orthobiologic medicine. They launched the Ciplostem, a new cell-based therapy designed for people who are suffering from grade II and III knee osteoarthritis (OA). This was developed by partnering with Stempeutics Research, and this therapy received approval from the Drug Controller General of India (DCGI). This marks a major advancement in the treatment options, especially for knee joint degeneration.
DCGI—Why this launch matters:
Usually, knee osteoarthritis is commonly seen in older people, but now it is no longer limited to older people. According to the latest studies, over 48 million Indians were affected with this condition in 2021, and the numbers were increasing only especially among the young generation with inactive lifestyles, sports injuries, or obesity realted joint stress.
Osteoarthritis is becoming challenging because of the existing treatments like physiotherapy, painkillers, heat therapy, and other supplements that give instant relief. These things keep the condition progressing only but do not address the underlying degeneration. This challenge has created a huge need for novel treatment options that do more than mask pain. That’s where Cipla’s new therapy enters.
What exactly is Ciplostem?
Ciplostem is a single-dose injection, which means it is directly administered into the knee joint. This therapy uses cells that work at the biological level to reduce inflammation, improve mobility, and support long-standing knee pain.
According to Cipla, patients may experience benefits that last up to two years, according to the clinical outcomes. Ciplostem is not just a short-term pain relief option, but it acts as a disease-modifying therapy.
How does it work?
Instead of simply suppressing the pain, this therapy targets the cellular level that is responsible for the joint inflammation and cartilage deterioration. This is the reason why it has become a promising option for people who are suffering from grade II and III OA.
Cipla’s global chief medical officer, Dr Jaipradeep Gogtay, also commented that the company wants to bring a validated therapy that is clinically proven to help patients overcome pain and gain mobility for a long time after the injection.
A timely innovation for India:
As lifestyle diseases are increasing, bone-and-joint disorders are also becoming common. Many patients ignore knee replacement surgeries due to financial issues, medical or personal reasons. A therapy like Ciplostem offers a middle path for people who want meaningful relief without any invasive procedure right away.
With this launch, Cipla has entered the rapidly growing field of regenerative and orthobiologic medicine. This therapy brings hope of long-lasting pain relief and improved mobility. As awareness grows, more therapies like this will become a valuable option for millions of people who are struggling with everyday knee pain and joint stiffness.
